Mark J Levis

Professor

1992 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Mark J Levis is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 9 Similar Profiles
Acute Myeloid Leukemia Medicine & Life Sciences
Protein-Tyrosine Kinases Medicine & Life Sciences
Mutation Medicine & Life Sciences
Leukemia Medicine & Life Sciences
fms-Like Tyrosine Kinase 3 Medicine & Life Sciences
4'-N-benzoylstaurosporine Medicine & Life Sciences
Cytarabine Medicine & Life Sciences
Bone Marrow Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1992 2019

Homologous Transplantation
Acute Myeloid Leukemia
Prospective Studies
Transplants
Survival

Arsenic and old FLT3

Levis, M. J., Mar 28 2019, In : Blood. 133, 13, p. 1392-1393 2 p.

Research output: Contribution to journalArticle

Arsenic

Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Smith, C. C., Levis, M. J., Perl, A. E., Martinelli, G., Neubauer, A., Berman, E., Montesinos, P., Baer, M. R., Larson, R. A., Chou, W. C., Yokoyama, H., Recher, C., Yoon, S. S., Hill, J. E., Rosales, M. & Bahceci, E., Nov 13 2019, In : Blood. 134, 1, 1 p.

Research output: Contribution to journalArticle

Acute Myeloid Leukemia
Refractory materials
Recurrence
Advisory Committees
Mutation
Acute Promyelocytic Leukemia
Fibrinogen
Heparin
Hemorrhage

FLT3 inhibitor maintenance after allogeneic transplantation: Is a placebo-controlled, randomized trial ethical?

for the Blood and Marrow Transplant Clinical Trials Network, Jan 1 2019, In : Journal of Clinical Oncology. 37, 19, p. 1604-1607 4 p.

Research output: Contribution to journalComment/debate

Homologous Transplantation
Randomized Controlled Trials
Placebos
Maintenance